Neratinib

Neratinib
	File:Neratinib skeletal.svg
Systematic (IUPAC) name
	(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
Clinical data
Routes of; administration	Oral
Identifiers
CAS Number	698387-09-6
ATC code	none
PubChem	CID 9915743
Chemical data
Formula	C30H29ClN6O3
Molar mass	557.04 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Neratinib (HKI-272) is a tyrosine kinase inhibitor^[1]^[2] under investigation for the treatment breast cancer^[3] and other solid tumours.

Clinical trials

It will be included in the forthcoming I-SPY2 breast cancer trial.^[5]

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This pharmacology-related article is a stub. You can help ssf by expanding it.

↑ "Definition of neratinib - National Cancer Institute Drug Dictionary". Retrieved 2008-12-01.
↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
↑ ClinicalTrials.gov NCT00398567 A Phase 1/2 Study Of HKI-272 In Combination With Herceptin In Subjects With Advanced Breast Cancer
↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
↑ http://www.reuters.com/article/idUSN1612347120100317 "Breast cancer study aims to speed drugs, cooperation" March 2010